6z13 - Revision history

OCA at 13:39, 24 January 2024

OCA — Wed, 24 Jan 2024 13:39:41 GMT

←Older revision		Revision as of 13:39, 24 January 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6z13]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z13 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z13 FirstGlance]. <br>		<table><tr><td colspan='2'>[[6z13]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z13 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z13 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene>, <scene name='pdbligand=NLE:NORLEUCINE'>NLE</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.8Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene>, <scene name='pdbligand=NLE:NORLEUCINE'>NLE</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z13 OCA], [https://pdbe.org/6z13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z13 RCSB], [https://www.ebi.ac.uk/pdbsum/6z13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z13 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z13 OCA], [https://pdbe.org/6z13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z13 RCSB], [https://www.ebi.ac.uk/pdbsum/6z13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z13 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.	+	[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>	+	[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>

	==See Also==		==See Also==

OCA at 07:11, 8 September 2022

OCA — Thu, 08 Sep 2022 07:11:32 GMT

←Older revision		Revision as of 07:11, 8 September 2022
Line 1:		Line 1:

-	====	+	==VEGF-A 13:107 crystallized with 3C bicyclic peptide==
-	<StructureSection load='6z13' size='340' side='right'caption='[[6z13]]' scene=''>	+	<StructureSection load='6z13' size='340' side='right'caption='[[6z13]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6z13]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z13 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z13 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z13 OCA], [https://pdbe.org/6z13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z13 RCSB], [https://www.ebi.ac.uk/pdbsum/6z13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z13 ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene>, <scene name='pdbligand=NLE:NORLEUCINE'>NLE</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z13 OCA], [https://pdbe.org/6z13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z13 RCSB], [https://www.ebi.ac.uk/pdbsum/6z13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z13 ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
		+	== Function ==
		+	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>
		+
		+	==See Also==
		+	*[[VEGF 3D Structures\|VEGF 3D Structures]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Z-~~disk~~]]	+	[[Category: Synthetic construct]]
		+	[[Category: Broussy S]]
		+	[[Category: Gaucher J-F]]
		+	[[Category: Reille-Seroussi M]]

OCA at 09:16, 26 May 2021

OCA — Wed, 26 May 2021 09:16:09 GMT

←Older revision		Revision as of 09:16, 26 May 2021
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6z13 ~~is ON HOLD until May 12 2022~~	+	====
-		+	<StructureSection load='6z13' size='340' side='right'caption='[[6z13]]' scene=''>
-	~~Authors~~: ~~Gaucher, J~~.-F.~~, Broussy, S~~.~~, Reille~~-~~Seroussi, M~~.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description~~: ~~VEGF-A 13~~:~~107 crystallized with 3C bicyclic peptide~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z13 OCA], [https://pdbe.org/6z13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z13 RCSB], [https://www.ebi.ac.uk/pdbsum/6z13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z13 ProSAT]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[~~[Category~~: ~~Gaucher~~, J.-F]]	+	__TOC__
-	[[Category: ~~Broussy, S~~]]	+	</StructureSection>
-	[[Category: ~~Reille~~-~~Seroussi, M~~]]	+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA: Protected "6z13" [edit=sysop:move=sysop]

OCA — Wed, 20 May 2020 04:31:05 GMT

Protected "6z13" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:31, 20 May 2020

OCA: New page: '''Unreleased structure''' The entry 6z13 is ON HOLD until May 12 2022 Authors: Gaucher, J.-F., Broussy, S., Reille-Seroussi, M. Description: VEGF-A 13:107 crystallized with 3C bicycli...

OCA — Wed, 20 May 2020 04:31:04 GMT

New page: '''Unreleased structure''' The entry 6z13 is ON HOLD until May 12 2022 Authors: Gaucher, J.-F., Broussy, S., Reille-Seroussi, M. Description: VEGF-A 13:107 crystallized with 3C bicycli...

New page

'''Unreleased structure'''

The entry 6z13 is ON HOLD until May 12 2022

Authors: Gaucher, J.-F., Broussy, S., Reille-Seroussi, M.

Description: VEGF-A 13:107 crystallized with 3C bicyclic peptide
[[Category: Unreleased Structures]]
[[Category: Gaucher, J.-F]]
[[Category: Broussy, S]]
[[Category: Reille-Seroussi, M]]